New Breast Cancer Drug May Reduce Risk of Disease Progression or Death by 50%
A study published on June 5 in The New England Journal of Medicine shows that a drug called Enhertu can lower the risk of disease progression and death from low metastatic breast cancer by 50%.
The drug is an antibody-chemotherapy combination distributed through an IV, and is able to block a protein known as HER2 on cancer cells, and can also attack the cancer inside of the cells to slow cancer progression.
A press release from the manufacturers of the drug, AstraZeneca and Daiichi Sankyo, indicates that the drug targets a protein that drives breast cancer growth and can decrease the chances of tumors.
The study findings show that patients who received the drug had their cancer progression slowed and improved survival when compared with those who received standard chemotherapy.
The U.S. Food and Drug Administration previously provided a breakthrough status designation for the drug to be used to treat HER2-positive breast cancer in April 2022.
On Sunday the findings from the study were presented at an annual meeting held by the American Society of Clinical Oncology.
Alexa can be reached at [email protected]